These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 37233667)

  • 21. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.
    Ishibashi S; Yamashita S; Arai H; Araki E; Yokote K; Suganami H; Fruchart JC; Kodama T;
    Atherosclerosis; 2016 Jun; 249():36-43. PubMed ID: 27062408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Low-Dose Pemafibrate Therapy for Hypertriglyceridemia in Patients with Type 2 Diabetes.
    Bando H; Taneda S; Manda N
    JMA J; 2021 Apr; 4(2):135-140. PubMed ID: 33997447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
    Honda A; Kamata S; Akahane M; Machida Y; Uchii K; Shiiyama Y; Habu Y; Miyawaki S; Kaneko C; Oyama T; Ishii I
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.
    Yokote K; Yamashita S; Arai H; Araki E; Suganami H; Ishibashi S; Of The K-Study Group OB
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30736366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
    Yokote K; Yamashita S; Arai H; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
    Cardiovasc Diabetol; 2021 May; 20(1):96. PubMed ID: 33947390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effects on renal function and glucose metabolism of renal dependent bezafibrate and non-renal dependent pemafibrate in patients with hypertriglyceridemia.
    Nishida M; Horio T; Fukuda Y; Hayakawa Y; Tateishi Y; Akai M; Emoto M; Hasegawa T; Imanishi M
    Int J Clin Pharmacol Ther; 2023 Oct; 61(10):437-444. PubMed ID: 37548458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.
    Iitake C; Masuda D; Koseki M; Yamashita S
    Cardiovasc Diabetol; 2020 Nov; 19(1):201. PubMed ID: 33246467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.
    Araki E; Yamashita S; Arai H; Yokote K; Satoh J; Inoguchi T; Nakamura J; Maegawa H; Yoshioka N; Tanizawa Y; Watada H; Suganami H; Ishibashi S
    Diabetes Care; 2018 Mar; 41(3):538-546. PubMed ID: 29298800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study.
    Katakura Y; Shimoda M; Ohnishi M; Kusano T; Dan K; Isobe H; Wamata R; Iwamoto Y; Fushimi Y; Sanada J; Obata A; Kimura T; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
    Nutr Metab Cardiovasc Dis; 2023 Jul; 33(7):1444-1452. PubMed ID: 37246074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor α modular (SPPARMα), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury.
    Konishi H; Miyauchi K; Onishi A; Suzuki S; Fuchimoto D; Shitara J; Endo H; Wada H; Doi S; Naito R; Ogita M; Dohi T; Kasai T; Daida H
    PLoS One; 2020; 15(11):e0241195. PubMed ID: 33201888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate.
    Yamashita S; Okazaki M; Okada T; Masuda D; Yokote K; Arai H; Araki E; Ishibashi S
    J Atheroscler Thromb; 2021 Sep; 28(9):974-996. PubMed ID: 33536398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Pemafibrate on Serum Creatinine in Patients with Chronic Kidney Disease.
    Imai E; Imai A
    JMA J; 2022 Jul; 5(3):328-333. PubMed ID: 35992291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice.
    Zhang Z; Diao P; Zhang X; Nakajima T; Kimura T; Tanaka N
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study.
    Komiya I; Yamamoto A; Sunakawa S; Wakugami T
    Lipids Health Dis; 2021 Feb; 20(1):17. PubMed ID: 33610176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elucidation of Molecular Mechanism of a Selective PPARα Modulator, Pemafibrate, through Combinational Approaches of X-ray Crystallography, Thermodynamic Analysis, and First-Principle Calculations.
    Kawasaki M; Kambe A; Yamamoto Y; Arulmozhiraja S; Ito S; Nakagawa Y; Tokiwa H; Nakano S; Shimano H
    Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31935812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion.
    Kitamura S; Murao N; Yokota S; Shimizu M; Ono T; Seino Y; Suzuki A; Maejima Y; Shimomura K
    BMC Res Notes; 2023 Sep; 16(1):202. PubMed ID: 37697384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα.
    Yamamoto Y; Takei K; Arulmozhiraja S; Sladek V; Matsuo N; Han SI; Matsuzaka T; Sekiya M; Tokiwa T; Shoji M; Shigeta Y; Nakagawa Y; Tokiwa H; Shimano H
    Biochem Biophys Res Commun; 2018 May; 499(2):239-245. PubMed ID: 29567478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SPPARM alpha: the Lazarus effect.
    Fruchart JC; Santos RD
    Curr Opin Lipidol; 2019 Dec; 30(6):419-427. PubMed ID: 31577610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review.
    Khan MS; Ghumman GM; Baqi A; Shah J; Aziz M; Mir T; Tahir A; Katragadda S; Singh H; Taleb M; Ali SS
    Am J Cardiovasc Drugs; 2023 Sep; 23(5):547-558. PubMed ID: 37524955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.